SCHEMBL879050

SCHEMBL879050

CC1=NC(=O)c2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 5/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
MAOA P21397 4/20 0.38
LMNA P02545 3/20 0.38
MAPT P10636 3/20 0.38
BLM P54132 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
RAB9A P51151 3/20 0.38
PLIN1 O60240 2/20 0.38
MAPK1 P28482 2/20 0.38
PLIN5 Q00G26 2/20 0.38
ABHD5 Q8WTS1 2/20 0.38
KDM4E B2RXH2 2/20 0.38
POLB P06746 2/20 0.38
CES1 P23141 2/20 0.38
NPC1 O15118 2/20 0.38
CES2 O00748 1/20 0.38
APAF1 O14727 1/20 0.38
TERT O14746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29492985 1.00 CDC25B (0.39) CDC25BMEN1KMT2AMAOALMNA
SCHEMBL2072302 0.76 CDC25B (0.39) CDC25BMEN1KMT2AMAOALMNA
SCHEMBL3697487 0.75 MEN1 (0.39) CDC25BMEN1KMT2AMAOALMNA
SCHEMBL17671420 0.75 MAOA (0.48) MAOAMAPTMAOBALDH1A1ELANE
SCHEMBL14455164 0.74 MAPK1 (0.44) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL30423822 0.73 CA1 (0.44) MEN1KMT2ASMN1; SMN2RAB9AMAPK1
SCHEMBL18786963 0.72 ESR2 (0.48) MAOAMAOBTTR
SCHEMBL20529361 0.72 S100A4 (0.48) MEN1KMT2AMAPTMAPK1KDM4E
SCHEMBL17141524 0.72 S100A4 (0.48) POLBCES1PTPRCS100A4RECQL
SCHEMBL19124739 0.72 S100A4 (0.48) LMNAMAPK1CES1S100A4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11884628-B2 Method for synthesizing lactam derivatives without use of catalyst GUIZHOU UNIVERSITY (CN) 2024-01-30 US claimed
WO-2022253252-A1 HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS SILEXON BIOTECH CO., LTD. (CN) 2022-12-08 WO claimed
US-20220177429-A1 METHOD FOR SYNTHESIZING LACTAM DERIVATIVES WITHOUT USE OF CATALYST GUIZHOU UNIVERSITY (CN) 2022-06-09 US claimed
WO-2020228170-A1 CATALYST-FREE SYNTHESIS METHOD FOR LACTAM DERIVATIVE 贵州大学 2020-11-19 WO claimed
EP-1784399-B1 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2011-06-15 EP claimed
JP-4674236-B2 2011-04-20 JP claimed
US-7910585-B2 Pyrimidine derivatives NOVARTIS AG (CH) 2011-03-22 US claimed
US-20080293708-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2008-11-27 US claimed
JP-2008510765-A 2008-04-10 JP claimed
CN-101006079-A Pyrimidine derivatives NOVARTIS AG (CH) 2007-07-25 CN claimed
EP-1784399-A2 PYRIMIDINE DERIVATIVES Novartis AG (CH) 2007-05-16 EP claimed
WO-2006021457-A2 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2006-03-02 WO claimed
US-20260109696-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2026-04-23 US disclosed
US-12590078-B2 2026-03-31 US disclosed
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF SIRONAX LTD (KY) 2026-03-19 US disclosed
US-20260078116-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2026-03-19 US disclosed
EP-1496838-A2 SUBSTITUTED AMIDES Merck & Co., Inc. (US) 2005-01-19 EP disclosed
WO-2004058145-A2 SUBSTITUTED AMIDES MERCK & CO., INC. (US) 2004-07-15 WO disclosed
US-20040058820-A1 Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis MERCK SHARP & DOHME LLC 2004-03-25 US disclosed
WO-2003077847-A2 SUBSTITUTED AMIDES MERCK & CO., INC. (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF NAMPT, NNMT, SARM1 CDC25B 3747/4885MEN1 2008/4885KMT2A 2737/4885
US-11884628-B2 Method for synthesizing lactam derivatives without use of catalyst COASY, SI, NAAA CDC25B 2596/4885MEN1 1464/4885KMT2A 321/4885
US-12590078-B2 ADRM1, USP19, USP1 CDC25B 2904/4885MEN1 3638/4885KMT2A 2342/4885
US-20040058820-A1 Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis CNR1, CNR2, MAG CDC25B 4081/4885MEN1 178/4885KMT2A 3170/4885
US-20220177429-A1 METHOD FOR SYNTHESIZING LACTAM DERIVATIVES WITHOUT USE OF CATALYST COASY, SI, NAAA CDC25B 2596/4885MEN1 1464/4885KMT2A 321/4885
US-20260078116-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, MCL1 CDC25B 459/4885MEN1 1248/4885KMT2A 2402/4885
US-20260109696-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS KRAS, MYC, NRAS CDC25B 598/4885MEN1 1555/4885KMT2A 1898/4885
US-20080293708-A1 Pyrimidine Derivatives DPYD, TYMP, TYMS CDC25B 408/4885MEN1 4489/4885KMT2A 3238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.